Sarah Ballou1, Alissa Beath2, Ted J Kaptchuk3, William Hirsch4, Thomas Sommers4, Judy Nee4, Johanna Iturrino4, Vikram Rangan4, Prashant Singh4, Mike Jones2, Anthony Lembo4. 1. Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts. Electronic address: sballou@bidmc.harvard.edu. 2. Department of Psychology, Macquarie University, Sydney, New South Wales, Australia. 3. Program in Placebo Studies, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts. 4. Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Abstract
BACKGROUND & AIMS: A high proportion of patients with irritable bowel syndrome (IBS) respond to placebo in clinical trials (estimated at about 40%). We aimed to identify factors that contribute to the high placebo response rate using data from a placebo-controlled trial of patients with IBS. METHODS: We performed a retrospective analysis of 599 women with IBS with constipation who were in theplacebo group of a 12-week, randomized, double-blind, phase 3 trial of the experimental medication renzapride. Primary analyses evaluated frequency of abdominal pain in patients who received placebo, defined as ≥30% pain improvement from baseline for ≥6 of the 12 study weeks. We performed backward elimination regression with bootstrapping to identify factors associated with response to placebo. RESULTS: In the placebo group, 29.0% of the patients had an abdominal pain response. Factors associated with a response to placebo were baseline variation in abdominal pain (odds ratio [OR], 1.71), maximum baseline pain severity (OR, 1.34), and placebo response in study week 2 (OR, 2.23) or week 3 (OR, 3.69). Factors associated with lack of response to placebo were number of baseline complete spontaneous bowel movements (OR, 0.73; P = .019) and final baseline pain ratings (OR, 0.73; P < .001). CONCLUSIONS: We identified factors associated with a response in abdominal pain to placebo using original data from an IBS clinical trial. Baseline factors associated with the placebo response in women with IBS and constipation included variation in baseline pain symptoms, severity of baseline symptoms, and early improvement of abdominal pain. These findings have significant implications for clinical trial design.
RCT Entities:
BACKGROUND & AIMS: A high proportion of patients with irritable bowel syndrome (IBS) respond to placebo in clinical trials (estimated at about 40%). We aimed to identify factors that contribute to the high placebo response rate using data from a placebo-controlled trial of patients with IBS. METHODS: We performed a retrospective analysis of 599 women with IBS with constipation who were in the placebo group of a 12-week, randomized, double-blind, phase 3 trial of the experimental medication renzapride. Primary analyses evaluated frequency of abdominal pain in patients who received placebo, defined as ≥30% pain improvement from baseline for ≥6 of the 12 study weeks. We performed backward elimination regression with bootstrapping to identify factors associated with response to placebo. RESULTS: In the placebo group, 29.0% of the patients had an abdominal pain response. Factors associated with a response to placebo were baseline variation in abdominal pain (odds ratio [OR], 1.71), maximum baseline pain severity (OR, 1.34), and placebo response in study week 2 (OR, 2.23) or week 3 (OR, 3.69). Factors associated with lack of response to placebo were number of baseline complete spontaneous bowel movements (OR, 0.73; P = .019) and final baseline pain ratings (OR, 0.73; P < .001). CONCLUSIONS: We identified factors associated with a response in abdominal pain to placebo using original data from an IBS clinical trial. Baseline factors associated with the placebo response in women with IBS and constipation included variation in baseline pain symptoms, severity of baseline symptoms, and early improvement of abdominal pain. These findings have significant implications for clinical trial design.
Authors: Alexander H Tuttle; Sarasa Tohyama; Tim Ramsay; Jonathan Kimmelman; Petra Schweinhardt; Gary J Bennett; Jeffrey S Mogil Journal: Pain Date: 2015-12 Impact factor: 6.961
Authors: Anthony J Lembo; Lisa Conboy; John M Kelley; Rosa S Schnyer; Claire A McManus; Mary T Quilty; Catherine E Kerr; Doug Drossman; Eric E Jacobson; Roger B Davis Journal: Am J Gastroenterol Date: 2009-06 Impact factor: 10.864
Authors: Ted J Kaptchuk; John M Kelley; Lisa A Conboy; Roger B Davis; Catherine E Kerr; Eric E Jacobson; Irving Kirsch; Rosa N Schyner; Bong Hyun Nam; Long T Nguyen; Min Park; Andrea L Rivers; Claire McManus; Efi Kokkotou; Douglas A Drossman; Peter Goldman; Anthony J Lembo Journal: BMJ Date: 2008-04-03
Authors: John T Farrar; Andrea B Troxel; Kevin Haynes; Ian Gilron; Robert D Kerns; Nathaniel P Katz; Bob A Rappaport; Michael C Rowbotham; Ann M Tierney; Dennis C Turk; Robert H Dworkin Journal: Pain Date: 2014-05-14 Impact factor: 6.961
Authors: Judy Nee; Katherine Salley; Andrew G Ludwig; Thomas Sommers; Sarah Ballou; Eve Takazawa; Sarah Duehren; Prashant Singh; Johanna Iturrino; Jesse Katon; Ha-Neul Lee; Vikram Rangan; Anthony J Lembo Journal: Clin Transl Gastroenterol Date: 2019-12 Impact factor: 4.488